EN DE
Watch NeurAxis, Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

NeurAxis, Inc (NRXS) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of NeurAxis, Inc stock $3.96, price $6.25, that is 36.6% below the price, quality 36 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

NI NeurAxis, Inc logo Thin data Nov 11, 2026

NeurAxis, Inc

NRXS · US
Very expensive, weak quality

Our calculation puts a fair price 37% below what the stock costs today.

Low debt
Revenue last quarter +116% vs. a year ago.
Expensive Growth (revenue 5y +13.1 %/yr in USD)
Fair value $3.96 · Strongly overvalued
Quality 36/100
Loss-making · -144.4% net margin (TTM)
Negative free cash flow
Trails peers (2/10)
Narrow moat 10/100 · thin data
Thin data
Estimate
Watch NeurAxis, Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$8.81 $1.60 Fair Value $3.96 Aug 2023 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

39‑month range $1.60 – $8.81 · fair‑value band $2.97 – $4.95 · the $6.25 price screens above the $3.96 fair value. As of Nov 11, 2026.

Follow NeurAxis in your weekly email

Every Wednesday you see whether NeurAxis is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States.

Show moreShow less

It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms.

The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders. It sells its products to healthcare companies, such as hospitals and clinics.

The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.

Stock analysis

NeurAxis, Inc (NRXS) currently trades at $6.25, while our estimate is $3.96, 37% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $2.97 (bear) to $4.95 (bull), the price of $6.25 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

NeurAxis, Inc reported revenue of $3.6M in FY2025 versus $2.7M in FY2021, a compound +7.0%/yr. Reported net income was −$7.8M in FY2025.

Key figures

Market cap $83.0M Micro · P/S ratio 15.6 · EPS (TTM) $−0.8300 · Net margin −144% · Return on equity −140% · Return on assets (EBIT) −440% (5-year average) · Operating margin −110% · Revenue (TTM) $5.3M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 29% below its 52-week high and 171% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −37%, NRXS screens richer than that median.

Fair Value

Bear $2.97 Fair Value $3.96 Bull $4.95
Price $6.25 · Downside -36.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 36/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 24
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 69
Debt, balance sheet and risk of trouble
Investment 50
Does it invest with discipline instead of growing at any price?
Low Volatility 16
How calm the share price moves, does not count
Price momentum 52
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 80
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • BuyBrian Allen CarricoChief Executive Officer, Director8,060 shares at $1.96$15,798Apr 1, 2026
  • BuyThomas Joeseph CarricoCRO, CCO, CPO667 shares at $1.96$1,307Apr 1, 2026
  • BuyTimothy Robert HenrichsChief Financial Officer7,593 shares at $1.96$14,882Apr 1, 2026
  • BuyBrian Hannasch10% owner80,000 shares at $4.79$382,800Feb 12, 2026
  • BuyGil AharonDirector286,138 shares at $3.52$1.0MDec 23, 2025
  • Plan buyTimothy Robert HenrichsChief Financial Officer1,937 shares at $4.84$9,375Oct 8, 2026
  • Plan buyThomas Joeseph CarricoCRO, CCO, CPO328 shares at $4.84$1,588Oct 8, 2026
  • Plan buyBrian Allen CarricoChief Executive Officer, Director268 shares at $4.84$1,297Oct 8, 2026

Plus 7 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 42/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+32.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.1%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−213.5% (2020) → −219.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

NRXS screens overvalued: fair value 37% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare NeurAxis, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 36 · Below median
Fair Value upside −36.6% · Below median
Profitability
Return on assets −121.8% · Bottom 25%
Net margin (12 months) −144.4% · Bottom 25%
Operating margin (12 months) −110.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 115.7% · Top 25%
Balance sheet
Debt / equity 0.02× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 24.42× · Priciest 25%
P/S (12 months) 15.61× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)99 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs NRXS
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs NRXS
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs NRXS
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs NRXS
argenx SE ARGX $971.55 $908.40 −7% vs NRXS
CSL Limited CSL A$201.68 A$181.40 −10% vs NRXS
Moderna, Inc MRNA $250.83 $158.70 −37% vs NRXS
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs NRXS
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs NRXS
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs NRXS

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

NeurAxis, Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "NeurAxis, Inc Fair Value". https://www.fairvalue-calculator.com/stock/NRXS

Frequently asked questions

Is NeurAxis, Inc (NRXS) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is $3.96 versus a price of $6.25, about 37% lower (overvalued).
What is the fair value of NRXS?
Our estimate for NeurAxis, Inc is $3.96 (as of Nov 11, 2026), built from audited fundamentals. The current price: $6.25.
What is the quality score of NRXS?
NeurAxis, Inc has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NeurAxis, Inc (NRXS)?
Our calculated price target is the estimate of $3.96 (as of Nov 11, 2026). Cautious scenario $2.97, optimistic scenario $4.95. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the NeurAxis, Inc stock forecast for 2026?
Our estimate puts fair value at $3.96, about 37% lower versus a price of $6.25 (overvalued). Cautious scenario $2.97, optimistic scenario $4.95. The calculation is refreshed regularly with new filings.
What is the revenue of NeurAxis, Inc (NRXS)?
NeurAxis, Inc reported trailing-twelve-month revenue of about $5.3M (latest available figure, as of Nov 11, 2026).
What is the intrinsic value of NeurAxis, Inc (NRXS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NeurAxis, Inc it is $3.96 per share (as of Nov 11, 2026), against a price of $6.25.
Is NeurAxis, Inc stock overvalued or undervalued in 2026?
As of Nov 11, 2026, NRXS trades above its calculated fair value: price $6.25, fair value $3.96, a gap of about −37% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NRXS?
No. The price is what the market pays today ($6.25); the fair value is what the company's own numbers justify ($3.96). For NeurAxis, Inc the two are $2.29 per share apart. That gap is exactly why we show both numbers side by side.
How much is NeurAxis, Inc worth?
The market values NeurAxis, Inc at about $83.0M (market capitalisation, as of Nov 11, 2026). Per share that is $6.25; our models calculate a fair value of $3.96 per share.
What do the bullish and bearish scenarios say about NRXS?
Our models span a range for NeurAxis, Inc: cautious scenario $2.97, base $3.96, optimistic $4.95 per share (as of Nov 11, 2026, price $6.25). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of NeurAxis, Inc (NRXS)?
Balance-sheet figures for NeurAxis, Inc (as of Nov 11, 2026): return on equity −139.8%, debt of 0.02 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is NRXS from its 52-week high?
NeurAxis, Inc trades at $6.25, about 29% below its 52-week high of $8.81 and 171% above the low of $2.31 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $3.96 is for.
Which stocks are comparable to NeurAxis, Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NeurAxis, Inc stock attractive at the current price?
The data as of Nov 11, 2026: price $6.25, calculated fair value $3.96 (−37%), Quality Score 36/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. NeurAxis, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of NeurAxis, Inc (NRXS)?
The closing price on Nov 10, 2026 was $6.25. Our estimate is $3.96, about 37% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with NeurAxis, Inc right now?
The price sits above even our optimistic bull case ($4.95). The favourable scenario is already priced in. Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of NeurAxis, Inc

How large is the market capitalisation of NeurAxis, Inc (NRXS)?
The market capitalisation of NeurAxis, Inc is $83.0M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of NeurAxis, Inc (NRXS)?
The price-to-sales ratio of NeurAxis, Inc is 15.6 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of NeurAxis, Inc (NRXS)?
Earnings per share at NeurAxis, Inc are $−0.8300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of NeurAxis, Inc (NRXS)?
The net margin of NeurAxis, Inc is −144% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of NeurAxis, Inc (NRXS)?
The return on equity (ROE) of NeurAxis, Inc is −140% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of NeurAxis, Inc (NRXS)?
On an EBIT basis the return on assets of NeurAxis, Inc is −440% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of NeurAxis, Inc (NRXS)?
The operating margin of NeurAxis, Inc is −110% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at NeurAxis, Inc (NRXS)?
Revenue at NeurAxis, Inc is growing +116% versus a year earlier (3y avg +10.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does NeurAxis, Inc (NRXS) generate?
The free cash flow of NeurAxis, Inc is −$6.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does NeurAxis, Inc (NRXS) hold?
NeurAxis, Inc holds more cash than debt, $4.5M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch NeurAxis, Inc in the live analysis

One click puts NeurAxis, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.